102 related articles for article (PubMed ID: 3512115)
21. Phase I clinical trial of isophosphamide (NSC-109724).
Cohen MH; Creaven PJ; Tejada F; Hansen HH; Muggia F; Mittelman A; Selawry OS
Cancer Chemother Rep; 1975; 59(4):751-5. PubMed ID: 1100226
[TBL] [Abstract][Full Text] [Related]
22. High-dose mitoxantrone and cyclophosphamide without stem cell support in high-risk and advanced solid tumors: a phase I trial.
Pérez-Gracia JL; Colomer R; Ruiz-Casado A; Arcediano A; Tornamira MV; Gómez-Martin C; Valentin V; Mendiola C; Cortés-Funes H; Hornedo J
Bone Marrow Transplant; 2001 Jan; 27(2):117-23. PubMed ID: 11281378
[TBL] [Abstract][Full Text] [Related]
23. Phase I study of weekly high-dose human lymphoblastoid interferon.
Connors JM; Silver HK
Cancer Treat Rep; 1984 Sep; 68(9):1093-6. PubMed ID: 6478449
[TBL] [Abstract][Full Text] [Related]
24. Clinical trial of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon alpha-2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991.
Wadler S; Atkins M; Karp D; Neuberg D; Haynes H; Dutcher JP
Cancer J Sci Am; 1998; 4(4):261-8. PubMed ID: 9689985
[TBL] [Abstract][Full Text] [Related]
25. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer.
Takano M; Kikuchi Y; Kita T; Suzuki M; Ohwada M; Yamamoto T; Yamamoto K; Inoue H; Shimizu K
Anticancer Res; 2002; 22(3):1833-8. PubMed ID: 12168878
[TBL] [Abstract][Full Text] [Related]
26. Trofosfamide in the treatment of patients with cancer. A pilot trial.
Falkson G; Falkson HC
S Afr Med J; 1978 Jun; 53(22):886-8. PubMed ID: 356287
[TBL] [Abstract][Full Text] [Related]
27. Apoptotic death induced by the cyclophosphamide analogue mafosfamide in human lymphoblastoid cells: contribution of DNA replication, transcription inhibition and Chk/p53 signaling.
Goldstein M; Roos WP; Kaina B
Toxicol Appl Pharmacol; 2008 May; 229(1):20-32. PubMed ID: 18289623
[TBL] [Abstract][Full Text] [Related]
28. Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation.
Roberts JD; Poplin EA; Tombes MB; Kyle B; Spicer DV; Grant S; Synold T; Moran R
Cancer Chemother Pharmacol; 2000; 45(2):103-10. PubMed ID: 10663624
[TBL] [Abstract][Full Text] [Related]
29. Phase I Study of Amrubicin and Cyclophosphamide in Patients With Advanced Solid Organ Malignancies: HOG LUN 07-130.
Jalal SI; Hanna N; Zon R; Masters GA; Borghaei H; Koneru K; Badve S; Prasad N; Somaiah N; Wu J; Yu Z; Einhorn L
Am J Clin Oncol; 2017 Aug; 40(4):329-335. PubMed ID: 25503432
[TBL] [Abstract][Full Text] [Related]
30. Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial.
Löffler TM; Freund W; Lipke J; Hausamen TU
Semin Oncol; 1996 Dec; 23(6 Suppl 16):32-4. PubMed ID: 9007118
[TBL] [Abstract][Full Text] [Related]
31. Intensified adjuvant cyclophosphamide, methotrexate and 5-fluorouracil therapy: a dose-finding study for ambulatory patients with breast cancer.
Hietanen P; Teerenhovi L; Joensuu H
Oncology; 1999; 56(2):103-9. PubMed ID: 9949294
[TBL] [Abstract][Full Text] [Related]
32. High-dose cyclophosphamide (NSC-26271) for the treatment of metastatic testicular neoplasms.
Buckner CD; Clift RA; Fefer A; Funk DD; Glucksberg H; Neiman PE; Paulsen A; Storb R; Thomas ED
Cancer Chemother Rep; 1974; 58(5 Pt 1):709-14. PubMed ID: 4609599
[No Abstract] [Full Text] [Related]
33. Phase I trial of teroxirone.
Neidhart JA; Derocher D; Grever MR; Kraut EH; Malspeis L
Cancer Treat Rep; 1984 Sep; 68(9):1115-9. PubMed ID: 6478450
[TBL] [Abstract][Full Text] [Related]
34. Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934).
LoRusso P; Foster BJ; Poplin E; McCormick J; Kraut M; Flaherty L; Heilbrun LK; Valdivieso M; Baker L
Clin Cancer Res; 1995 Dec; 1(12):1487-93. PubMed ID: 9815948
[TBL] [Abstract][Full Text] [Related]
35. In vitro marrow purging in chronic myelogenous leukemia: effect of mafosfamide and recombinant granulocyte--macrophage colony-stimulating factor.
Carlo-Stella C; Mangoni L; Piovani G; Almici C; Garau D; Caramatti C; Rizzoli V
Bone Marrow Transplant; 1991 Oct; 8(4):265-73. PubMed ID: 1756324
[TBL] [Abstract][Full Text] [Related]
36. Design of new oxazaphosphorine anticancer drugs.
Liang J; Huang M; Duan W; Yu XQ; Zhou S
Curr Pharm Des; 2007; 13(9):963-78. PubMed ID: 17430192
[TBL] [Abstract][Full Text] [Related]
37. Phase I trial of homoharringtonine administered by prolonged continuous infusion.
Neidhart JA; Young DC; Kraut E; Howinstein B; Metz EN
Cancer Res; 1986 Feb; 46(2):967-9. PubMed ID: 3940656
[TBL] [Abstract][Full Text] [Related]
38. Phase I study of spirogermanium given daily.
Legha SS; Ajani JA; Bodey GP
J Clin Oncol; 1983 May; 1(5):331-6. PubMed ID: 6668504
[TBL] [Abstract][Full Text] [Related]
39. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
[TBL] [Abstract][Full Text] [Related]
40. Autologous marrow transplantation in acute lymphoblastic leukemia: control of residual disease with mafosfamide and induction of syngeneic GVHD with cyclosporin. The Italian Mafosfamide Study Group.
Rizzoli V; Carella AM; Carlo-Stella C; Mangoni L
Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():76-8. PubMed ID: 2202474
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
